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Every year, the month of September is celebrated as 
Leukaemia & Lymphoma Awareness Month. This is 
done to increase the general public’s understanding 
regarding cancers of hematologic origin and their 
early warning symptoms. The main aim of making 
this effort is to enhance the people’s knowledge about 
the prevalence of these life-threatening conditions, 
and also to point people to trusted information 
resources, so that the likelihood of early detection is 
increased and better outcome is achieved. Many of 
the affected people are able to successfully get treated 
and overcome these conditions and are also able to 
maintain a high quality of life, all due to recent 
research advances.  
 
The cancers that affect the blood or bone marrow are 
scientifically known as leukaemias and lymphomas. 
 
Leukaemia is a kind of cancer that initiates in the 
blood forming tissues and most of the blood cells 
develop from stem cells found in the bone marrow. 
Leukaemia cells are abnormal white blood cells that 
are formed in a person suffering from leukaemia. 
These leukaemia cells don't die when they should, 
unlike normal blood cells. They make it hard for 
normal blood cells to do their work. 
 
According to federal statistics, in 2019, adult 
leukaemias are expected to account for around 3.5 
percent of all new cancer cases, with leukaemia being 
the most common cancer in children less than 15 
years of age. 
 
Leukaemia’s are classified into four major types: 
AML, acute myeloid leukaemia, that affects myeloid 
cells and has a quick growth; CLL, chronic 
lymphocytic leukaemia, affecting lymphoid cells and 
has a slow growth; ALL, acute lymphocytic leukaemia 
affecting lymphoid cells and has a quick growth; and 
lastly CML, chronic myeloid leukaemia which has an 
effect on myeloid cells and usually has a slow growth 
initially. Adults are mainly affected by AML and CLL 
while ALL is the most common leukaemia affecting  
 
 
 
the children. 
 
Despite successful treatment, childhood leukaemia 
stands as the principal subtype of paediatric cancer 
with enigmatic etiology. Researchers have proposed a 
plethora of candidate environmental exposures, but 
almost all of them lack a biological rationale or 
consistent epidemiological evidence.1  
 
Lymphatic system is a part of the human immune 
system where the lymphomas originate. Lymphoma 
can initiate anywhere in the human body due to 
throughout presence of the lymphatic tissue. These 
can be basically classified into two categories, 
Hodgkin and non-Hodgkin lymphomas. 
 
The presence of a Reed-Sternberg cell in the lymph 
nodes is the marking characteristic of Hodgkin 
lymphoma and this lymphoma may occur commonly 
in patients affected by acquired immunodeficiency 
syndrome. 
 
Categorized by scientists typically as either slow-
growing or aggressive, Non-Hodgkin lymphomas 
include a vast, diversified group of cancers of immune 
system cells, with diffuse large B-cell lymphoma and 
follicular lymphoma being the most common types of 
NHL in adults. According to the National Cancer 
Institute, these lymphoma represents approximately 
4.2 percent of all new cancer cases in the United 
States of America. Both kind of lymphomas can occur 
in children and adults. 
 
Timely and accurate estimation and detection 
followed by precise assessment of therapeutic 
treatment response is of prime importance for the 
optimal management of subjects affected with 
lymphoma. Over the last 5 decades, drastic advances 
in technological development has led to 
establishment of imaging as the cornerstone for 
evaluation of disease. But the appropriate application 
of current techniques requires thorough knowledge 
of   their    strengths   and weaknesses, along with the  
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appreciation of the huge diversity of neoplasms of 
lymphoid tissue.2 
 
In the year 1949, a society was established as the de 
Villiers Foundation. In the year 2000, its name was 
changed from The Leukaemia Society of America to 
The Leukaemia & Lymphoma Society (LLS). This 
initiative was taken to emphasize the commitment of 
society against fighting all blood-borne cancers. The 
inaugural edition of the Report to the Nation on 
Blood Cancer: Leading the Way to Cancer Cures in 
2017 was released to provide education and get people 
engaged in the battle against blood cancers namely, 
lymphomas, leukaemia’s and myelomas which stand 
at third position in the list of leading causes of cancer 
related deaths in United States of American. In the 
same year, the U.S. Food and Drug Administration 
approved unrivalled treatment options (eighteen in 
number) for subjects who were in urgent need. For all 
of these advancements, the Leukaemia & Lymphoma 
Society has played a vital role and in recent decades, 
the research supported by this body has significantly 
contributed to almost every new blood cancer 
treatment strategy and innovative approach 
including immunotherapy and precision medicine.3 
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